SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India gains on receiving USFDA approval for Metformin ER Tablets

20 Mar 2018 Evaluate

Granules India is currently trading at Rs. 109.20, up by 0.90 points or 0.83% from its previous closing of Rs. 108.30 on the BSE.

The scrip opened at Rs. 108.20 and has touched a high and low of Rs. 109.40 and Rs. 108.20 respectively. So far 4435 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 157.00 on 18-May-2017 and a 52 week low of Rs. 101.95 on 11-Aug-2017.

Last one week high and low of the scrip stood at Rs. 114.55 and Rs. 107.00 respectively. The current market cap of the company is Rs. 2749.06 crore.

The promoters holding in the company stood at 44.94%, while institutions and non-institutions held 18.36% and 36.70% respectively.

Granules India has received approval from the US Food & Drug Administration (USFDA) for Abbreviated New Drug Application (ANDA) for Metformin Extended Release (ER) Tablets 500 mg and 750 mg. The approved ANDA is the bioequivalent to the reference listed drug product (RLD), Glucophage XR tablets of Bristol Myers Squibb. The company intends to commercialize this product shortly.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

679.15 24.75 (3.78%)
20-Apr-2026 09:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.45
Dr. Reddys Lab 1235.10
Cipla 1233.00
Zydus Lifesciences 939.95
Lupin 2330.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×